Characteristics of tumor infiltration by adoptively transferred and endogenous natural‐killer cells in a syngeneic rat model: Implications for the mechanism behind anti‐tumor responses

Interleukin‐2‐activated, cultured NK cells (A‐NK) cells were adoptively transferred into a syngeneic rat liver‐tumor model. The kinetics of tumor infiltration by NK cells, originating either from adoptively transferred or from endogenous sources, the localization of these cells in the tumor, and their interactions with extracellular‐matrix proteins were studied by immunohistochemistry and transmission‐electron microscopy. The adoptive transfer of A‐NK cells via the hepatic artery and s.c. injections of IL‐2 into rats bearing sub‐capsularly induced CC531 liver tumors, but also IL‐2 monotherapy, resulted in a significant increase of the number of NK cells both at the tumor border and in the tumor center. The majority of tumor‐infiltrating NK cells was present in the tumor stroma and only occasionally was an NK cell observed in a tumor nodule in direct contact with tumor cells. Observations by electron microscopy suggested that matrix proteins, abundantly present in the tumor stroma but absent in the tumor nodules, provide a substrate for migration of infiltrating cells, whereas tight structures of matrix proteins surrounding tumor nodules provide a barrier for establishment of direct NK‐cell‐to‐tumor‐cellcontact. Our results suggest that direct NK‐cell‐to‐target‐cell‐contact‐mediated lysis is of minor importance for attaining an anti‐tumor effect in this model. We hypothesize that treatment of tumor‐bearing rats with A‐NK cells and/or IL‐2 initiates a cascade of events (e.g., secretion of tumor‐killing cytokines and/or infiltration of other immune cells) ultimately leading to tumor regression. Int. J. Cancer 78:783–789, 1998. © 1998 Wiley‐Liss, Inc.

[1]  G. Fleuren,et al.  Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti‐tumor response than systemic administration , 1998, International journal of cancer.

[2]  G. Fleuren,et al.  Characterization of three new membrane structures on rat NK cells which are involved in activation of the lytic machinery. , 1997, Immunobiology.

[3]  K. Okumura,et al.  Enhancement of lymphokine-activated killer cell activity by fibronectin. , 1997, Journal of immunotherapy.

[4]  U. Nannmark,et al.  Migration of IL‐2‐activated natural killer cells in vitro: influence of extracellular matrix proteins , 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[5]  E. Engleman,et al.  Immune regulation: a critical link between NK cells and CTLs. , 1996, Immunology today.

[6]  T. Whiteside,et al.  Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer. , 1996, Cancer research.

[7]  U. Nannmark,et al.  Ultrastructure of interactions between activated murine natural killer cells and melanoma cells in an extracellular matrix (Matrigel) environment. , 1996, Natural immunity.

[8]  S. Hauser,et al.  Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane. , 1996, Journal of immunology.

[9]  P. Musiani,et al.  Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[10]  U. Nannmark,et al.  Microvessel origin and distribution in pulmonary metastases of B16 melanoma: implication for adoptive immunotherapy. , 1995, Cancer research.

[11]  R. Goldfarb,et al.  Non-granular proteolytic enzymes of rat interleukin-2-activated natural killer cells. III. Enhancement of A-NKP 1, 2, and 3 proteolytic activities (cleaving after Arg, Phe and Pro) in response to interleukin-2. , 1995, Natural immunity.

[12]  E. Engleman,et al.  Requirement for natural killer cells in the induction of cytotoxic T cells. , 1995, Journal of immunology.

[13]  M. Harada,et al.  Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes. , 1995, Immunology.

[14]  G. Fleuren,et al.  The infiltration of experimentally induced lung metastases of colon carcinoma CC531 by adoptively transferred interleukin‐2‐activated natural killer cells in wag rats , 1994, International journal of cancer.

[15]  R. Goldfarb,et al.  Zymographic analysis of extracellular, released and cell-associated proteases of rat interleukin 2-activated natural killer (A-NK) cells. , 1994, In vivo.

[16]  R. Goldfarb,et al.  Accumulation of adoptively transferred A-NK cells in murine metastases: kinetics and role of interleukin-2. , 1994, In vivo.

[17]  T. Whiteside,et al.  Rapid Il-2-induced adherence of human natural killer cells. Expression of mRNA for cytokines and IL-2 receptors in adherent NK cells. , 1993, Journal of immunology.

[18]  S. Steinberg,et al.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. , 1993, Journal of the National Cancer Institute.

[19]  P. Kuppen,et al.  Liver metastasis model of colon cancer in the rat: immunohistochemical characterization. , 1993, Invasion & metastasis.

[20]  R. Goldfarb,et al.  Nongranular proteolytic enzymes of rat IL-2-activated natural killer cells. I. Subcellular localization and functional role. , 1992, Journal of immunology.

[21]  G. Fleuren,et al.  Biodistribution of lymphokine‐activated killer (LAK) cells in WAG rats after hepatic‐artery or jugular‐vein infusion , 1992, International journal of cancer.

[22]  S. Ratner,et al.  Lymphocyte development of adherence and motility in extracellular matrix during IL-2 stimulation. , 1992, Journal of immunology.

[23]  R. Goldfarb,et al.  Tissue distribution of adoptively transferred adherent LAK cells: role of the route of administration. , 1992, Natural immunity.

[24]  T. Whiteside,et al.  Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells. , 1992, Journal of immunology.

[25]  G. Fleuren,et al.  T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. I. Significant bispecific lysis of syngeneic colon carcinoma CC531 is critically dependent on prolonged preactivation of effector T-lymphocytes by immobilized anti-T-cell receptor antibody. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[26]  U. Nannmark,et al.  Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases , 1991, The Journal of experimental medicine.

[27]  U. Nannmark,et al.  Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells. , 1991, Journal of the National Cancer Institute.

[28]  R. Jain,et al.  Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation. , 1991, Journal of the National Cancer Institute.

[29]  E. Saksela,et al.  Fibronectin facilitates the migration of human natural killer cells , 1991, European journal of immunology.

[30]  E. Wisse,et al.  Electron microscopic observations on the accumulation of large granular lymphocytes (pit cells) and kupffer cells in the liver of rats treated with continuous infusion of interleukin‐2 , 1990, Hepatology.

[31]  A. Deleo,et al.  Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells , 1989, The Journal of experimental medicine.

[32]  R. Schwarz,et al.  Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic. , 1989, Cancer research.

[33]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[34]  R. Timpl,et al.  Laminin and other basement membrane components. , 1987, Annual review of cell biology.

[35]  S. Rosenberg,et al.  Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. , 1985, Journal of immunology.

[36]  S. Rosenberg,et al.  Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. , 1985, Cancer research.

[37]  J. Jeekel,et al.  Interferon treatment of a transplantable rat colon adenocarcinoma: Importance of tumor site , 1984, International journal of cancer.